Financials Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-20 EDT 5-day change 1st Jan Change
5.94 USD +0.51% Intraday chart for Altimmune, Inc. -10.14% -47.20%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 28.38 417 363.1 808.4 604.4 419 - -
Enterprise Value (EV) 1 28.38 417 363.1 697.3 469.3 355.1 162.4 275.6
P/E ratio -1.18 x -5.91 x -3.9 x -9.09 x -6.78 x -7.02 x -4.69 x -3.33 x
Yield - - - - - - - -
Capitalization / Revenue 4.89 x 50.9 x 82.3 x -11,889 x 1,419 x 13.4 x 16.8 x -
EV / Revenue 4.89 x 50.9 x 82.3 x -10,255 x 1,102 x 11.4 x 6.5 x -
EV / EBITDA - - -3.77 x -7.93 x - -3.72 x -1.48 x -2.29 x
EV / FCF - -12 x -4.02 x -11.1 x -6.19 x -4.42 x -1.58 x -1.68 x
FCF Yield - -8.31% -24.9% -8.99% -16.2% -22.6% -63.3% -59.6%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 15,015 36,968 39,644 49,146 53,729 70,902 - -
Reference price 2 1.890 11.28 9.160 16.45 11.25 5.910 5.910 5.910
Announcement Date 3/27/20 2/25/21 3/15/22 2/28/23 3/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5.801 8.185 4.41 -0.068 0.426 31.25 25 -
EBITDA 1 - - -96.36 -87.94 - -95.37 -110 -120.3
EBIT 1 -21.46 -54.8 -85.54 -87.74 -83.51 -61.74 -109 -179
Operating Margin -370% -669.5% -1,939.62% 129,029.41% -19,603.29% -197.55% -435.86% -
Earnings before Tax (EBT) 1 -20.58 -54.46 -97.09 -84.91 -88.45 -49.07 -141.6 -180.2
Net income 1 -20.52 -49.04 -97.09 -84.71 -88.45 -59.05 -141.6 -180.2
Net margin -353.71% -599.2% -2,201.43% 124,577.94% -20,762.21% -188.96% -566.4% -
EPS 2 -1.600 -1.910 -2.350 -1.810 -1.660 -0.8417 -1.260 -1.775
Free Cash Flow 1 - -34.64 -90.36 -62.71 -75.86 -80.3 -102.8 -164.3
FCF margin - -423.22% -2,048.7% 92,223.53% -17,806.81% -256.94% -411.33% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/27/20 2/25/21 3/15/22 2/28/23 3/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 3.278 0.032 0.008 0.002 -0.11 0.021 0.006 0.362 0.037 0.005 0.00062 31.25 0.00125 - -
EBITDA 1 -23.87 -19.38 -20.34 -24.89 -23.27 -21.4 -17.5 -21.99 - -26.69 -19.9 -20.4 -20.9 - -
EBIT 1 -20.68 -19.5 -20.4 -24.75 -23.09 -21.76 -18.01 -22.54 -21.2 -26.79 -25.23 15.28 -25.13 -28.21 -32.94
Operating Margin -631.08% -60,934.38% -254,937.5% -1,237,600% 20,994.55% -103,614.29% -300,116.67% -6,226.52% -57,308.11% -535,880% -4,069,785.48% 48.91% -2,010,026.4% - -
Earnings before Tax (EBT) 1 -23.89 -19.43 -20.11 -23.71 -21.66 -20.07 -16.06 -20.67 -31.64 -24.39 -24.17 24.43 -24.54 -25.7 -30.4
Net income 1 -23.89 -19.43 -20.11 -23.52 -21.66 -20.07 -16.06 -20.67 -31.64 -24.39 -24.78 15.65 -25.28 -25.7 -30.4
Net margin -728.85% -60,718.75% -251,337.5% -1,175,800% 19,690.91% -95,590.48% -267,683.33% -5,710.22% -85,516.22% -487,880% -3,996,237.1% 50.07% -2,022,760% - -
EPS 2 -0.5700 -0.4400 -0.4200 -0.4800 -0.4400 -0.4000 -0.3200 -0.3900 -0.5400 -0.3400 -0.3450 0.1867 -0.3450 -0.3433 -0.3533
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/15/22 5/12/22 8/11/22 11/10/22 2/28/23 5/11/23 8/10/23 11/7/23 3/27/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - 111 135 63.9 257 143
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -34.6 -90.4 -62.7 -75.9 -80.3 -103 -164
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 0.2 12.1 0.13 0.05 0.15 0.5 2.5
Capex / Sales - 2.49% 274.74% -185.29% 11.03% 0.48% 2% -
Announcement Date 3/27/20 2/25/21 3/15/22 2/28/23 3/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5.91 USD
Average target price
20.57 USD
Spread / Average Target
+248.08%
Consensus
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Financials Altimmune, Inc.